These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9802364)

  • 1. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats.
    Pène J; Desroches A; Paradis L; Lebel B; Farce M; Nicodemus CF; Yssel H; Bousquet J
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):571-8. PubMed ID: 9802364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract.
    Ewbank PA; Murray J; Sanders K; Curran-Everett D; Dreskin S; Nelson HS
    J Allergy Clin Immunol; 2003 Jan; 111(1):155-61. PubMed ID: 12532112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen.
    Reefer AJ; Carneiro RM; Custis NJ; Platts-Mills TA; Sung SS; Hammer J; Woodfolk JA
    J Immunol; 2004 Mar; 172(5):2763-72. PubMed ID: 14978075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for cat asthma.
    Van Metre TE; Marsh DG; Adkinson NF; Kagey-Sobotka A; Khattignavong A; Norman PS; Rosenberg GL
    J Allergy Clin Immunol; 1988 Dec; 82(6):1055-68. PubMed ID: 2462581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects.
    Simons FE; Imada M; Li Y; Watson WT; HayGlass KT
    Int Immunol; 1996 Dec; 8(12):1937-45. PubMed ID: 8982778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
    Shamji MH; Singh I; Layhadi JA; Ito C; Karamani A; Kouser L; Sharif H; Tang J; Handijiev S; Parkin RV; Durham SR; Kostic A; Orengo JM; DeVeaux M; Kamal M; Stahl N; Yancopoulos GD; Wang CQ; Radin AR
    Am J Respir Crit Care Med; 2021 Jul; 204(1):23-33. PubMed ID: 33651675
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of peptide therapy on ex vivo T-cell responses.
    Marcotte GV; Braun CM; Norman PS; Nicodemus CF; Kagey-Sobotka A; Lichtenstein LM; Essayan DM
    J Allergy Clin Immunol; 1998 Apr; 101(4 Pt 1):506-13. PubMed ID: 9564804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections.
    Senti G; Crameri R; Kuster D; Johansen P; Martinez-Gomez JM; Graf N; Steiner M; Hothorn LA; Grönlund H; Tivig C; Zaleska A; Soyer O; van Hage M; Akdis CA; Akdis M; Rose H; Kündig TM
    J Allergy Clin Immunol; 2012 May; 129(5):1290-6. PubMed ID: 22464647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1.
    Haselden BM; Syrigou E; Jones M; Huston D; Ichikawa K; Chapman MD; Kay AB; Larché M
    J Allergy Clin Immunol; 2001 Sep; 108(3):349-56. PubMed ID: 11544452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.
    Niespodziana K; Focke-Tejkl M; Linhart B; Civaj V; Blatt K; Valent P; van Hage M; Grönlund H; Valenta R
    J Allergy Clin Immunol; 2011 Jun; 127(6):1562-70.e6. PubMed ID: 21411130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evidence of efficacy and safety of a polymerized cat dander extract for allergen immunotherapy.
    Morales M; Gallego M; Iraola V; Taulés M; de Oliveira E; Moya R; Carnés J
    BMC Immunol; 2017 Feb; 18(1):10. PubMed ID: 28235411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract.
    Nanda A; O'connor M; Anand M; Dreskin SC; Zhang L; Hines B; Lane D; Wheat W; Routes JM; Sawyer R; Rosenwasser LJ; Nelson HS
    J Allergy Clin Immunol; 2004 Dec; 114(6):1339-44. PubMed ID: 15577832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sublingual immunotherapy with cat epithelial extract. Personal experience].
    Sánchez Palacios A; Schamann F; García JA
    Allergol Immunopathol (Madr); 2001; 29(2):60-5. PubMed ID: 11450599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy.
    Benjaponpitak S; Oro A; Maguire P; Marinkovich V; DeKruyff RH; Umetsu DT
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):468-75. PubMed ID: 10069882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I.
    Briner TJ; Kuo MC; Keating KM; Rogers BL; Greenstein JL
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7608-12. PubMed ID: 8356062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy.
    Grundström J; Neimert-Andersson T; Kemi C; Nilsson OB; Saarne T; Andersson M; van Hage M; Gafvelin G
    Int Arch Allergy Immunol; 2012; 157(2):136-46. PubMed ID: 21985799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy decreases skin sensitivity to cat extract.
    Van Metre TE; Marsh DG; Adkinson NF; Kagey-Sobotka A; Khattignavong A; Norman PS; Rosenberg GL
    J Allergy Clin Immunol; 1989 May; 83(5):888-99. PubMed ID: 2654256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy.
    Rudulier CD; Tonti E; James E; Kwok WW; Larché M
    Allergy; 2019 Nov; 74(11):2157-2166. PubMed ID: 31077596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial.
    Oldfield WL; Larché M; Kay AB
    Lancet; 2002 Jul; 360(9326):47-53. PubMed ID: 12114041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy.
    Martínez-Gómez JM; Johansen P; Rose H; Steiner M; Senti G; Rhyner C; Crameri R; Kündig TM
    Allergy; 2009 Jan; 64(1):172-8. PubMed ID: 19076537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.